Mustang Bio Opens CAR-T Cell-Therapy Manufacturing FacilityBy
Mustang Bio, a New York-headquartered clinical-stage biopharmaceutical company and a subsidiary of the biopharmaceutical company, Fortress Biotech, has opened a chimeric antigen receptor (CAR) T-cell cell-therapy manufacturing facility at the UMass Medicine Science Park in Worcester, Massachusetts.
The 27,000-square-foot facility has been designed to support the clinical development and commercialization of Mustang’s CAR-T product candidates and enable proprietary cell-therapy research.
The initial build‐out of the facility has been completed, and Mustang Bio says it anticipates processing patient cells by the end of 2018. The facility will initially be used in the clinical development of Mustang’s three lead CAR-T product candidates for treating: acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm, B‐cell non‐Hodgkin lymphoma, and glioblastoma.
“…[E]stablishing in‐house cell therapy research capabilities will enable us to continue to differentiate our product candidates through innovation in cell processing and the evaluation of immuno‐oncology technologies, like checkpoint antibodies and oncolytic viruses, in combination with our CAR Ts,” said Manuel Litchman, President and Chief Executive Officer of Mustang, in a June 22, 2018 company release. “We look forward to building our clinical and chemistry, manufacturing and controls teams in Worcester and anticipate filing our first investigational new drug application in late 2018 for MB‐102 in acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm.”
Source: Mustang Bio